Anti-Fibrinolytic Drugs - Netherlands

Netherlands

In the Netherlands, the revenue in the Anti-Fibrinolytic Drugs market is estimated to reach €83.93m in 2024.
It is anticipated that the revenue will exhibit a compound annual growth rate (CAGR 2024-2029) of 4.44%, leading to a market volume of €104.30m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, amounting to €9,047.00m in 2024.
In the Netherlands, the demand for anti-fibrinolytic drugs is increasing due to the country's aging population and rising prevalence of cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Netherlands has been showing steady growth in recent years.

Customer preferences: Customers in Netherlands have been increasingly seeking anti-fibrinolytic drugs due to the rise in the number of surgeries and trauma cases. These drugs are used to prevent excessive bleeding during and after surgery. Additionally, the aging population in Netherlands has also contributed to the growth of the market as older individuals are more prone to bleeding disorders.

Trends in the market: The market for anti-fibrinolytic drugs in Netherlands is expected to continue growing due to the increasing number of surgeries and trauma cases. In addition, the rising prevalence of bleeding disorders such as hemophilia is also expected to drive the demand for these drugs. The market is also witnessing a shift towards the use of newer and more effective drugs.

Local special circumstances: Netherlands has a well-developed healthcare system and a high level of healthcare spending. This has contributed to the growth of the anti-fibrinolytic drugs market in the country. Additionally, the country has a high incidence of bleeding disorders such as hemophilia, which has further boosted the demand for these drugs.

Underlying macroeconomic factors: The growth of the anti-fibrinolytic drugs market in Netherlands is also influenced by macroeconomic factors such as GDP growth, healthcare spending, and government policies. The country has a strong economy and a high level of healthcare spending, which has contributed to the growth of the market. Additionally, the government has implemented policies to improve access to healthcare, which has also supported the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.